# A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors

> **NCT02923349** · PHASE1,PHASE2 · COMPLETED · sponsor: **Incyte Biosciences International Sàrl** · enrollment: 87 (actual)

## Conditions studied

- Advanced Malignancies
- Metastatic Cancer

## Interventions

- **DRUG:** INCAGN01949

## Key facts

- **NCT ID:** NCT02923349
- **Lead sponsor:** Incyte Biosciences International Sàrl
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-31
- **Primary completion:** 2019-03-26
- **Final completion:** 2019-03-26
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2025-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02923349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02923349, "A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02923349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*